1. Home
  2. YDES vs PRLD Comparison

YDES vs PRLD Comparison

Compare YDES & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

YDES

YD Bio Limited Ordinary Shares

HOLD

Current Price

$4.18

Market Cap

543.0M

Sector

N/A

ML Signal

HOLD

Logo Prelude Therapeutics Incorporated

PRLD

Prelude Therapeutics Incorporated

HOLD

Current Price

$5.36

Market Cap

529.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YDES
PRLD
Founded
2013
2016
Country
Taiwan
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
543.0M
529.1M
IPO Year
2024
2020

Fundamental Metrics

Financial Performance
Metric
YDES
PRLD
Price
$4.18
$5.36
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$5.67
AVG Volume (30 Days)
174.8K
562.6K
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.21
EPS
N/A
N/A
Revenue
N/A
$12,140,000.00
Revenue This Year
N/A
$320.10
Revenue Next Year
N/A
$100.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
73.43
52 Week Low
$1.70
$0.98
52 Week High
$25.00
$6.83

Technical Indicators

Market Signals
Indicator
YDES
PRLD
Relative Strength Index (RSI) 57.16 47.73
Support Level $1.99 $3.92
Resistance Level $5.15 $5.62
Average True Range (ATR) 0.84 0.48
MACD -0.09 -0.14
Stochastic Oscillator 49.21 10.54

Price Performance

Historical Comparison
YDES
PRLD

About YDES YD Bio Limited Ordinary Shares

YD Bio Ltd is a biopharmaceutical company focusing on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. Stem cell therapy uses versatile cells to repair or regenerate damaged tissues, offering innovative treatments for injuries, degenerative diseases, and immune disorders with potential for personalized medicine and tissue engineering.

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a precision oncology company developing medicines in areas of high unmet need for cancer patients. Its pipeline features selective KAT6A degraders and mutant selective JAK2V617F JH2 inhibitors, new approaches to clinically validated targets with transformative potential for patients. The company is also leveraging its expertise in targeted protein degradation to discover and develop next-generation degrader antibody conjugates (DACs) with novel payloads.

Share on Social Networks: